The size of the Asia-Pacific Cardiovascular Therapeutic Drugs is a USD 28.53 billion market in 2021 and is projected to reach USD 32.44 billion by 2026, growing with a cumulative annual growth rate (CAGR) of 2.6%. Several new and effective drug therapies for cardiovascular disorders have been development in the past few decades. With the rising prevalence of cardiovascular diseases, the market for therapeutics drugs is likely to grow in the future.
Cardiovascular drugs include medicines or drugs that are administered for the diseases that are related to the function and structure of blood vessels and heart. While cardiovascular disorders continue to be leading cause of death globally, the major disorders include heart failure, high cholesterol, coronary artery disease and blood clots among others.
Cardiovascular diseases remain the common cause of mortality and morbidity across the globe and is an emerging threat. The driving factors for the cardiovascular therapeutics includes growing per capita medical spending, rising aging population and epidemic of general medical problems which includes obesity and diabetes. However, there are few restraints faced by the market which includes high costs involving drug development and lowering of target population. Cardiovascular diseases remain the common cause of mortality and morbidity across the globe and is an emerging threat. Despite its extensive existence, many of the drug development pipelines has been stagnant for variety of factors.
Asia-Pacific market for cardiovascular therapeutic drugs market is segmented into diseases and drug class. Based on the type of cardiovascular diseases, the market is studied as hypertension, thrombosis, hyperlipidaemia, Arteriosclerosis, Coronary artery disease, Peripheral artery disease, Cardiac arrhythmias, acute coronary syndrome, Myocardial infarction, cardiac failure diseases and other diseases. Asia-Pacific market based on its geographical regions, is segmented into China, Japan, India, South Korea and Australia.
Some of the major companies leading in the industry includes Bayer, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, Novartis, Merck, Takeda, Sanofi, Pfizer and boehringer ingelheim.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Disease
5.1.1 Arteriosclerosis
5.1.2 Cardiac arrhythmias
5.1.3 Myocardial infarction
5.1.4 Acute Coronary Syndrome
5.1.5 Peripheral artery disease
5.1.6 Coronary artery disease
5.1.7 Hypertension
5.1.8 Hyperlipidaemia
5.1.9 Thrombosis
5.1.10 Cardiac failure diseases
5.1.11 Others
5.2 By Drug Class
5.2.1 Monotherapies
5.2.2 Combination Therapies
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 AstraZeneca
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Novartis
9.3 Bristol-Myers Squibb
9.4 Pfizer
9.5 Sanofi
9.6 Merck
9.7 Bayer
9.8 Takeda
9.9 Boehringer Ingelheim
9.10 Johnson & Johnson
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
